Life Sciences

  • August 31, 2026

    Zimmer Wins Hip Implant Suit After Expert Testimony Tossed

    A New York federal judge handed Zimmer Inc. an early win in a multidistrict litigation case alleging its hip prosthetics are faulty, after finding that the plaintiff's only expert witness could not testify because his opinion that the device was defective was based solely on the fact that it broke.

  • August 31, 2026

    9th Circ. Won't Rehear Eye Drop Antitrust Suit Despite Dissent

    A forceful dissent from a pair of Ninth Circuit judges wasn't enough to keep the full appellate court from letting stand a panel decision preserving wholesalers' district court win accusing the maker of Clear Eyes drops of illegal price discrimination favoring Costco.

  • August 31, 2026

    How Did Litigants Fare In Judge Albright's 55 Patent Trials?

    U.S. District Judge Alan Albright oversaw more than 50 patent trials between his 2018 arrival on the bench and planned Monday departure, and in a surprise for many attorneys, there was a near-even split between victories for patent owners and accused infringers.

  • August 31, 2026

    Defamation Litigation Roundup: NYT, J&J, Azerbaijan

    In this month's review of defamation fights, Law360 details a jury verdict against The New York Times in a suit involving its reporting on a shooting in Alabama, and highlights a judge's decision to spare researchers from a suit by a Johnson & Johnson subsidiary over their talc research.

  • August 31, 2026

    SEC, FDA Enter Info-Sharing Pact To Bolster Enforcement

    The U.S. Securities and Exchange Commission and U.S. Food and Drug Administration are looking to bolster information-sharing related to FDA-regulated products in a bid to help each other in their respective oversight and compliance efforts, according to a three-year memorandum of understanding the agencies announced Monday.

  • August 31, 2026

    Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win

    The Federal Circuit on Monday rejected MSN Laboratories' argument that three Exelixis patents on the blockbuster cancer drug Cabometyx are invalid, while dismissing as moot an appeal on a fourth patent, a ruling Exelixis said will block MSN's generic version until 2030.

  • August 31, 2026

    Judge Rejects AstraZeneca's Attack On Colo. 340B Law

    A Colorado federal judge on Monday granted the state's motion to dismiss AstraZeneca's complaint challenging a state law that expands distribution of drugs discounted through a federal program, finding that the state law isn't preempted or unconstitutional.

  • August 31, 2026

    9 More Drug Cos. Make Pricing Agreements With US

    Nine more branded drug manufacturers reached deals cutting prices on their medications, President Donald Trump announced Monday, with nearly 90% of such products now being covered by "most-favored nation" deals in the United States.

  • August 31, 2026

    Hospital Ex-Exec Pleads Not Guilty To $239M Testing Fraud

    A former Chicago hospital executive who stopped fighting extradition to face fraud, money laundering, embezzlement and several other U.S. criminal charges pled not guilty Monday to prosecutors' accusation that he stole more than $239 million in a COVID-19 testing fraud scheme.

  • August 31, 2026

    Holland & Knight Adds Duo From McDermott Lobbying Arm

    Holland & Knight LLP has grown its federal government affairs practice in the nation's capital with the addition of an attorney and senior director from McDermott+, the now-closed consulting and lobbying affiliate of McDermott Will & Schulte, the firm said Monday.

  • August 31, 2026

    Rising Star: Cooley's Bill Roegge

    Bill Roegge of Cooley LLP has advised life sciences companies on several notable transactions, including cancer genomics company Personalis and vaccine maker Dynavax in their respective blockbuster buyouts from Tempus and Sanofi, earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 31, 2026

    Mead Johnson Prevails In 1st Infant Formula MDL Trial

    An Illinois federal jury sided with Mead Johnson on Monday in a lawsuit claiming its infant formula caused a premature baby boy to develop a fatal intestinal disease, rejecting his mother's claims that the company should be held liable for making a defective product and failing to adequately warn doctors of the risks associated with it.

  • August 31, 2026

    Ropes-Steered Lilly To Buy Goodwin-Led Merida For $2.9B

    Eli Lilly and Co., advised by Ropes & Gray LLP, said Monday that it has agreed to pay up to $2.875 billion in cash to purchase autoimmune- and allergic disease-focused biotech Merida Biosciences Inc., which is being advised by Goodwin Procter LLP.

  • August 28, 2026

    Mead Johnson, Mom Clash On Formula Risks In Trial Closing

    An Illinois federal jury is set to begin deliberating Monday on a mother's claims that Mead Johnson is liable for her infant son's death, with attorneys making closing remarks Friday in the first test case to be tried among more than 800 consolidated lawsuits linking a deadly bowel condition to premature baby formula.

  • August 28, 2026

    AbbVie 'Concocted' Cancer Drug IP Claims, Biotech Firm Says

    Biotech firms ProfoundBio and Genmab urged a Seattle federal judge Thursday to throw out rival AbbVie's lawsuit accusing two of its former employees of taking trade secrets on cancer therapies to ProfoundBio, arguing AbbVie's claims are time-barred, and the information wasn't a protectable trade secret.

  • August 28, 2026

    Walmart Pays $50M To End DOJ's Suit Over Opioid Crisis

    Walmart has agreed to pay $50 million to settle the U.S. Department of Justice's nearly 6-year-old lawsuit in Delaware federal court alleging the big-box retailer helped spur the nationwide opioid crisis by unlawfully dispensing controlled drugs from its pharmacies, the department announced Friday.

  • August 28, 2026

    Mylan, Lannett, Others Can't Split Up Humana Generics Trial

    A Pennsylvania federal judge refused Friday to let Mylan, Lannett and other generic-drug makers split up Humana's looming price-fixing trial between liability and damages, preferring a single go in front of a single jury for the first trial in the sprawling multidistrict litigation.

  • August 28, 2026

    AI-Bolstered Drug Co. Hits Ch. 11 With $105M Debt

    A company that uses artificial intelligence to explore new uses for existing drugs entered bankruptcy in Delaware with over $104 million in debt and a stalking horse bidder.

  • August 28, 2026

    Parse Owes $4.9M In Cell Analysis Patent Case, Jury Finds

    A Delaware federal jury put Parse Biosciences Inc. on the hook for $4.9 million after finding Friday that the biotechnology company infringed a trio of Roche Sequencing Solutions Inc. patents covering a way of detecting target molecules in cell samples.

  • August 28, 2026

    Rising Star: Ropes & Gray's Ray Grant

    Ray Grant of Ropes & Gray LLP advised Bain Capital portfolio company Tanabe Pharma Corp. in a $2.5 billion sale of the global rights to a treatment for ALS, earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 28, 2026

    Medical Marijuana Industry Grapples With DEA's New Role

    After years of allowing the state-sanctioned medical marijuana industry to operate without interference, the U.S. Drug Enforcement Administration is stepping in to regulate a drug it once treated exclusively as contraband, but attorneys and regulators say the cannabis industry's interactions with the agency are off to a rocky start.

  • August 28, 2026

    Fla. Says PBMs Fixed Prices For Prescription Drugs

    Florida's attorney general on Thursday sued two competing pharmacy benefit managers for allegedly colluding to fix prescription drug reimbursement rates to pharmacies, which the state said threatens Floridians' access to affordable medications.

  • August 28, 2026

    4 Arguments For Benefits Attys To Watch In September

    The Fifth Circuit will weigh Louisiana's bid to block telehealth access to the abortion drug mifepristone, while the Fourth Circuit will hear Lockheed Martin's challenge to a trial court decision that kept a pension de-risking suit alive. Here's a look at these and other argument sessions that should be on benefits attorneys' radar next month.

  • August 27, 2026

    PBMs Hammer Opioid Judge In Last-Ditch Gambit At 6th Circ.

    An Ohio federal judge knowingly flouted a Sixth Circuit rebuke by forcing two of the largest remaining defendants in multidistrict opioid litigation to either "settle for enormous sums or litigate for years hundreds of cases," says a Thursday petition urging the appeals court to intervene.

  • August 27, 2026

    Albertsons Loses Bid For Midtrial Win In Wash. Opioid Case

    Albertsons can't escape the state of Washington's lawsuit accusing the pharmacy chain and its Safeway subsidiary of contributing to the state's opioid crisis, a state judge ruled Thursday in denying the company's bid to dismiss the case midtrial.

Expert Analysis

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

  • Opinion

    High Court's Abortion Pill Stay Reinforces Appellate Principles

    Author Photo

    The U.S. Supreme Court's recent order in Danco Laboratories v. Louisiana, staying a Fifth Circuit ruling that reinstated an in-person requirement for dispensing the abortion medicine mifepristone, should be seen not as a definitive ruling on reproductive rights, but as an affirmation of a more disciplined jurisdictional reality, says Daniel Nardo at Nardo & Associates.

  • Cannabis Policy Shift May Reshape Banking, Insolvency Risks

    Author Photo

    The Trump administration's cannabis rescheduling initiative aims to correct classification that had rendered federal banking, tax administration and insolvency law incoherent, and will begin to restore some alignment between federal law and the economic reality of the marijuana industry, says Richard Ormond at Buchalter.

  • Opinion

    International Patent Licensing System Must Be Maintained

    Author Photo

    As foreign approaches to patent enforcement threaten to distort the licensing markets that underpin modern technology, courts and policymakers must take action to ensure that the standard essential patent framework is preserved, says Brian O'Shaughnessy at Dinsmore.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.